Video

Dr. Levy on Future Research Directions for Lenvatinib in HCC

Anna T. Levy, DO, discuses future research directions for lenvatinib in patients with hepatocellular carcinoma.

Anna T. Levy, DO, an assistant professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, discuses future research directions for lenvatinib (Lenvima) in patients with hepatocellular carcinoma (HCC).

Lenvatinib is an active agent, having demonstrated superior progression-free survival compared with sorafenib (Nexavar) in the phase 3 REFLECT trial (NCT01761266), Levy says. Additionally, the agent has been shown to result in better patient-reported quality-of-life scores and overall high response rates, Levy adds.

However, questions regarding the efficacy of lenvatinib in patients with Child-Pugh B liver cirrhosis still need to be addressed, Levy explains. As with most TKIs, more research is needed to further examine the safety and tolerability of lenvatinib in this subgroup, Levy concludes.

Related Videos
Tanios Bekaii-Saab, MD, FACP
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.
Tanios Bekaii-Saab, MD, FACP
Michel Ducreux, MD, PhD, head, Gastrointestinal Oncology Unit, head, Gastrointestinal Oncology Tumor Board, Gustave Roussy; professor, oncology, Paris-Saclay University
Piotr Rutkowski, MD